Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
- Virtua Samson Cancer Center — Moorestown, New Jersey
- Morristown Medical Center — Morristown, New Jersey
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in New Jersey: - Cooper Hospital University Medical Center — Camden, New Jersey
- Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
- Englewood Hospital and Medical Center — Englewood, New Jersey
- Hackensack University Medical Center — Hackensack, New Jersey
- Morristown Medical Center — Morristown, New Jersey
Phase 3 Recruiting Academic/Other
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to der…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT06377852
Sites in New Jersey: - Penn Medicine - Princeton Health — Plainsboro, New Jersey
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in New Jersey: - Astera Cancer Care East Brunswick — East Brunswick, New Jersey
- Capital Health Regional Medical Center — Pennington, New Jersey
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 3 Recruiting Industry
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced…
Sponsor: AstraZeneca
NCT ID: NCT04862663
Sites in New Jersey: - Research Site — Camden, New Jersey
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in New Jersey: - Astera Cancer Care East Brunswick — East Brunswick, New Jersey
- Summit Medical Group — Florham Park, New Jersey
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in New Jersey: - Cooper University Health Care — Camden, New Jersey
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in New Jersey: - Hackensack Meridian Health — Hackensack, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients…
Sponsor: BeOne Medicines
NCT ID: NCT07492641
Sites in New Jersey: - Astera Cancer Care East Brunswick — East Brunswick, New Jersey
Phase 3 Recruiting Academic/Other
The purpose of this study is to compare using FDA-approved bupivacaine (a numbing medicine), along with the usual medications for post-operative pain control to using the usual medications for postoperative pain control alone. The addition…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT03351348
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Consent and follow-up only) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Consent and follow-up only) — Montvale, New Jersey
Phase 3 Recruiting Academic/Other
The purpose of this study to test whether a comprehensive program may help the lymph fluid to drain out of the arm and prevent lymphedema in participants with breast cancer.
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06144164
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in New Jersey: - Hunterdon Medical Center — Flemington, New Jersey
- Monmouth Medical Center Southern Campus — Lakewood, New Jersey
- Saint Barnabas Medical Center — Livingston, New Jersey
- Monmouth Medical Center — Long Branch, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in New Jersey: - MD Anderson Cancer Center at Cooper- Two Cooper Plaza — Camden, New Jersey
Phase 2 Recruiting Industry
The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT07102381
Sites in New Jersey: - Astera Cancer Care (Formerly Regional Cancer Care Associates) — East Brunswick, New Jersey
- Medical Oncology Hematology Associates — Newark, New Jersey
Phase 1, Phase 2 Recruiting Industry
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …
Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in New Jersey: - MD Anderson Cancer Center at Cooper — Camden, New Jersey
Phase 1, Phase 2 Recruiting Industry
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, seven …
Sponsor: Hoffmann-La Roche
NCT ID: NCT03424005
Sites in New Jersey: - Hackensack Univ Medical Center — Hackensack, New Jersey
- Regional Cancer Care Associates, LLC — Howell Township, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic…
Sponsor: Genentech, Inc.
NCT ID: NCT07100106
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 2 Recruiting Industry
This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESA…
Sponsor: GlaxoSmithKline
NCT ID: NCT04641247
Sites in New Jersey: - GSK Investigational Site — Morristown, New Jersey
Phase 1, Phase 2 Recruiting Industry
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatmen…
Sponsor: Hoffmann-La Roche
NCT ID: NCT04802759
Sites in New Jersey: - Regional Cancer Care Associates LLC (RCCA) - Freehold Location — Freehold, New Jersey
- Regional Cancer Care Associates LLC ? Howell Division — Howell Township, New Jersey
Phase 2 Recruiting Academic/Other
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
Sponsor: Rutgers, The State University of New Jersey
NCT ID: NCT05559164
Sites in New Jersey: - Trinitas Hospital and Comprehensive Cancer Center — Elizabeth, New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton — Hamilton, New Jersey
- RWJBarnabas Health - - Jersey City Medical Medical — Jersey City, New Jersey
- Monmouth Medical Center Southern Campus — Lakewood, New Jersey
- RWJBarnabas Health - Monmouth Medical Center — Long Branch, New Jersey
Phase 2 Recruiting Academic/Other
The researchers are doing this study to compare two different types of group therapy and find out whether they are effective approaches for helping breast cancer survivors manage joint pain caused by aromatase inhibitors (AI). This type of…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06728579
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
The purpose of this study is to look at how effective neoadjuvant (before surgery) endocrine therapy (NET) is in participants with invasive lobular carcinoma (ILC) who have breast-conserving surgery (BCS). The main purpose of the study is …
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07483307
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
This is an open-label phase 2 study to evaluate the pCR rate in patients diagnosed with HER2 positive breast cancer treated on an adaptive clinical trial design. Tumors will undergo testing using a novel molecular phosphoprotein-based biom…
Sponsor: Rutgers, The State University of New Jersey
NCT ID: NCT07402473
Sites in New Jersey: - RWJBarnabas Health - Trinitas Hospital and Comprehensive Cancer Center — Elizabeth, New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton — Hamilton, New Jersey
- RWJBarnabas Health - Monmouth Medical Center — Long Branch, New Jersey
- Rutgers Cancer Institute — New Brunswick, New Jersey
- RWJBarnabas Health - Newark Beth Israel Medical Center — Newark, New Jersey